Before
The therapy was in broad clinical use. But the literature lacked high-quality data on the criteria for selecting patients, when to start the therapy and how to dose it.
Case study · Blood purification therapy manufacturer · Intensive care · Therapy recommendation
Evidence-based therapy recommendations for extracorporeal blood purification.
3
Publications, peer-reviewed and open access

The therapy was in broad clinical use. But the literature lacked high-quality data on the criteria for selecting patients, when to start the therapy and how to dose it.
“Through a consistently cumulative scientific approach, supported by our long-standing scientific partner Dr. Recknagel, patient selection, timing and dosing could be addressed in a structured way and on a much more robust footing for the first time.”
Broad use alone does not convince a guideline committee. A series of publications that answers the open questions one after another lays the foundation for that.
Answer 18 short questions about your product. You then receive your Evidence Plan as a PDF: which building blocks must be ready by your next deadline, when you have to start at the latest, and what budget to expect.

This is what your result looks like (example)
In the evidence call, you hear in 30 minutes how we would answer it.
Data in the drawerHow does a survey of 26,000 women become a recognised publication?26.000Women, published and listed in PubMed
Indication extensionWhat evidence does the Notified Body need for the new indication?114patients in a retrospective study
Clinical standardHow does our application become the clinical standard?10Steps in the SOP, now widely applied
Market launchHow do we convince clinicians when the launch is in 4 weeks?4Weeks to the finished white paper